BACKGROUND AND PURPOSE: Intestinal mucositis refers to mucosal damage caused by cancer treatment, and irinotecan is one of the agents most associated with this condition. Focusing on the development of alternatives to prevent this important adverse effect, we evaluated the activity of the flavonoid luteolin, which has never been tested for this purpose despite its biological potential. EXPERIMENTAL APPROACH: The effects of luteolin were examined on irinotecan-induced intestinal mucositis in mice. Clinical signs were evaluated. Moreover, histological, oxidative, and inflammatory parameters were analysed, as well as the possible interference of luteolin in the anti-tumour activity of irinotecan. KEY RESULTS: Luteolin (30 mg·kg-1 ; p.o. or i.p.) prevented irinotecan-induced intestinal damage by reducing weight loss and diarrhoea score and attenuating the shortening of the duodenum and colon. Histological analysis confirmed that luteolin (p.o.) prevented villous shortening, vacuolization, and apoptosis of cells and preserved mucin production in the duodenum and colon. Moreover, luteolin treatment mitigated irinotecan-induced oxidative stress, by reducing the levels of ROS and LOOH and augmenting endogenous antioxidants, and inflammation by decreasing MPO enzymic activity, TNF, IL-1β, and IL-6 levels and increasing IL-4 and IL-10. Disruption of the tight junctions ZO-1 and occludin was also prevented by luteolin treatment. Importantly, luteolin did not interfere with the anti-tumour activity of irinotecan. CONCLUSION AND IMPLICATIONS: Luteolin prevents intestinal mucositis induced by irinotecan and therefore could be a potential adjunct in anti-tumour therapy to control this adverse effect, increasing treatment adherence and consequently the chances of cancer remission.
BACKGROUND AND PURPOSE:Intestinal mucositis refers to mucosal damage caused by cancer treatment, and irinotecan is one of the agents most associated with this condition. Focusing on the development of alternatives to prevent this important adverse effect, we evaluated the activity of the flavonoidluteolin, which has never been tested for this purpose despite its biological potential. EXPERIMENTAL APPROACH: The effects of luteolin were examined on irinotecan-induced intestinal mucositis in mice. Clinical signs were evaluated. Moreover, histological, oxidative, and inflammatory parameters were analysed, as well as the possible interference of luteolin in the anti-tumour activity of irinotecan. KEY RESULTS:Luteolin (30 mg·kg-1 ; p.o. or i.p.) prevented irinotecan-induced intestinal damage by reducing weight loss and diarrhoea score and attenuating the shortening of the duodenum and colon. Histological analysis confirmed that luteolin (p.o.) prevented villous shortening, vacuolization, and apoptosis of cells and preserved mucin production in the duodenum and colon. Moreover, luteolin treatment mitigated irinotecan-induced oxidative stress, by reducing the levels of ROS and LOOH and augmenting endogenous antioxidants, and inflammation by decreasing MPO enzymic activity, TNF, IL-1β, and IL-6 levels and increasing IL-4 and IL-10. Disruption of the tight junctions ZO-1 and occludin was also prevented by luteolin treatment. Importantly, luteolin did not interfere with the anti-tumour activity of irinotecan. CONCLUSION AND IMPLICATIONS: Luteolin prevents intestinal mucositis induced by irinotecan and therefore could be a potential adjunct in anti-tumour therapy to control this adverse effect, increasing treatment adherence and consequently the chances of cancer remission.
Authors: Stephen P H Alexander; Arthur Christopoulos; Anthony P Davenport; Eamonn Kelly; Alistair Mathie; John A Peters; Emma L Veale; Jane F Armstrong; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2019-12 Impact factor: 8.739
Authors: S Kwiecien; K Jasnos; M Magierowski; Z Sliwowski; R Pajdo; B Brzozowski; T Mach; D Wojcik; T Brzozowski Journal: J Physiol Pharmacol Date: 2014-10 Impact factor: 3.011
Authors: Andrea M Stringer; Rachel J Gibson; Richard M Logan; Joanne M Bowen; Ann S J Yeoh; Jessica Laurence; Dorothy M K Keefe Journal: Cancer Chemother Pharmacol Date: 2008-11-08 Impact factor: 3.333
Authors: Richard M Logan; Rachel J Gibson; Joanne M Bowen; Andrea M Stringer; Stephen T Sonis; Dorothy M K Keefe Journal: Cancer Chemother Pharmacol Date: 2007-08-17 Impact factor: 3.333
Authors: Stephen P H Alexander; Doriano Fabbro; Eamonn Kelly; Alistair Mathie; John A Peters; Emma L Veale; Jane F Armstrong; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2019-12 Impact factor: 8.739
Authors: Lázaro de Sousa Fideles; João Antônio Leal de Miranda; Conceição da Silva Martins; Maria Lucianny Lima Barbosa; Helder Bindá Pimenta; Paulo Vitor de Souza Pimentel; Claudio Silva Teixeira; Marina Alves Sampaio Scafuri; Samuel de Osterno Façanha; João Erivan Façanha Barreto; Poliana Moreira de Medeiros Carvalho; Ariel Gustavo Scafuri; Joabe Lima Araújo; Jefferson Almeida Rocha; Icaro Gusmão Pinto Vieira; Nágila Maria Pontes Silva Ricardo; Matheus da Silva Campelo; Maria Elenir Nobre Pinho Ribeiro; Gerly Anne de Castro Brito; Gilberto Santos Cerqueira Journal: Molecules Date: 2020-06-17 Impact factor: 4.411
Authors: Ameeduzzafar Zafar; Nabil K Alruwaili; Syed Sarim Imam; Omar Awad Alsaidan; Mohd Yasir; Mohammed M Ghoneim; Sultan Alshehri; Md Khalid Anwer; Alanood S Almurshedi; Abdullah S Alanazi Journal: Drug Deliv Date: 2021-12 Impact factor: 6.419